Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 17;9:642307. doi: 10.3389/fcell.2021.642307

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Feng, Barb, Allen, Regan and Saligan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Metabolic profiles of patients with non-metastatic prostate cancer with (+ADT, n = 58) or without androgen deprivation therapy (−ADT, n = 102). (A) Volcano plot of metabolites of the +ADT group compared to −ADT. The y axis represents p-value converted to negative log 10 scale, and the x axis represents log2 fold change. Significant metabolites (fold change > 1.5, FDR ≤ 0.1) were highlighted in red. (B) Pairwise PLSDA score plot of the top five components. (C) PLSDA two-dimensional plot ellipses representing 95% confidence intervals. (D) ROC curve demonstrating the specificity and sensitivity of the PLSDA model discriminating the +ADT group from the −ADT group. AUC = 0.839, 95% CI (0.725, 0.903). Excellent classification is indicated by an AUC > 0.90. (E) Metabolite set enrichment analysis (MSEA) of significant metabolites.